Pharmacotherapy for Fragile X Syndrome: Progress to Date
Matthew H Davenport1,2, Tori L Schaefer1, Katherine J Friedmann1
1Division of Child and Adolescent Psychiatry (MLC 4002), Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., Cincinnati, OH, 45229-3039, USA.
Drugs
|February 10, 2016
Summary
Currently, no approved treatments exist for Fragile X Syndrome (FXS). While drug development for FXS targets neurotransmission, recent clinical trials show limited success, necessitating new approaches.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Fragile X Syndrome (FXS) is a genetic disorder with no approved treatments.
- Current management focuses on symptoms, with limited success in targeted therapies.
- Understanding the Fragile X Mental Retardation Protein (FMRP) and its role in neurotransmission is key.
Purpose of the Study:
- To review the current landscape of Fragile X Syndrome (FXS) drug development.
- To discuss challenges and recent findings in FXS clinical trials.
- To summarize symptomatic treatments and future therapeutic directions for FXS.
Main Methods:
- Literature review of FXS pathophysiology and drug development.
- Analysis of recent clinical trial outcomes for FXS therapies.
- Summary of current symptomatic treatments and emerging strategies.
Main Results:
- Despite ongoing research, no targeted drug has been approved for FXS.
- Clinical trials targeting glutamate and GABA neurotransmission have shown limited efficacy.
- Metabotropic glutamate receptor 5 (mGluR5) antagonists have not proven effective.
Conclusions:
- FXS drug development faces significant challenges, questioning current clinical trial designs.
- Future FXS therapies may need to address multiple disrupted pathways.
- Development of objective outcome measures is crucial for advancing FXS treatment.
More Related Videos
11:10Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
Published on: July 6, 2022
2.7K
10:58TMS: Using the Theta-Burst Protocol to Explore Mechanism of Plasticity in Individuals with Fragile X Syndrome and Autism
Published on: December 28, 2010
17.6K
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
662
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
662
01:28Drug Therapy
392
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
392
01:23Antidepressant Drugs: MAOIs and Other Agents
1.2K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
01:29Pharmacogenomics: Identification of New Drug Targets
76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
108
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
108